FDA aligns with Imunon’s Phase III trial protocol for ovarian cancer treatment

Imunon has announced the alignment of the US Food and Drug Administration (FDA) with the Phase III OVATION 3 trial of IMNN-001 for ovarian cancer protocol.

IMNN-001, the company’s lead candidate, is being developed for treating women with newly diagnosed advanced ovarian cancer.